Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 21, 2015

View Archived Issues

First clinical trial results for nivolumab in ovarian cancer

Interaction of beta7-integrins and MAdCAM-1 shows promise as a therapeutic target for NASH

Purdue Pharma divulges opioid agonists

Spectrum Pharmaceuticals reaches agreement with FDA on SPA for of SPI-2012 trial

Binimetinib improves PFS in phase III melanoma trial compared with dacarbazine

NeuroRx plans IND application for Cyclurad for the treatment of acute suicidal crisis

Research Triangle Institute announces APJ agonists

Beijing Institute of Pharmacology and Toxicology reports mTOR inhibitors

MAT-2203 granted FDA QIDP and fast track designations for aspergillosis

Thomas Helledays Stiftelse For Medicinsk Forskning introduces MTH1 inhibitors

A*STAR presents Wnt pathway inhibitors

Soligenix's SGX-942 reduces duration of chemoradiotherapy-induced oral mucositis in phase II trial

ViiV Healthcare to acquire Bristol-Myers Squibb's HIV pipeline

Cells transduced with the inducible caspase-9 suicide gene well tolerated in children

Ohara Pharmaceutical submits NDA for crisantaspase in Japan

Roche patents oxytocin receptor agonists

Academia Sinica discloses antineoplastic deoxyelephantopin analogues

Guangzhou Magpie Pharmaceutical reports amantadine nitrate neuroprotectants

EMA committee recommends approval of lesinurad for hyperuricemia in gout

Interim phase I results of SGN-LIV1A

ABP-980 proved similar to FDA-licensed trastuzumab

Bayer's recombinant factor VIII BAY-81-8973 receives positive CHMP opinion

EMA CHMP recommends approval of AstraZeneca's osimertinib for NSCLC

EMA committee backs approval of Brilique 60 mg for patients with history of heart attack

Development of HCV nucleotide polymerase inhibitor AL-704 terminated

FDA schedules advisory committee review of eteplirsen NDA

Portola completes BLA submission for andexanet alfa

FDA approves Keytruda for first-line treatment of unresectable or metastatic melanoma

FDA grants breakthrough therapy designation to BI-1482694 for EGFR-mutant NSCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...